Valeritas Holdings Inc (NASDAQ:VLRX)’s share price traded down 5.5% during trading on Friday . The company traded as low as $1.65 and last traded at $1.71, 505,800 shares changed hands during trading. An increase of 52% from the average session volume of 332,016 shares. The stock had previously closed at $1.81.
A number of equities analysts recently commented on the company. ValuEngine upgraded Valeritas from a “hold” rating to a “buy” rating in a research report on Wednesday, September 4th. Zacks Investment Research upgraded Valeritas from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a research report on Saturday, July 13th. Oppenheimer lifted their price objective on Valeritas from $1.25 to $12.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 9th. Finally, BTIG Research reiterated a “buy” rating and set a $14.00 price objective on shares of Valeritas in a research report on Sunday, August 11th.
The stock has a market cap of $10.09 million, a PE ratio of -0.05 and a beta of 1.92. The company has a quick ratio of 2.06, a current ratio of 2.58 and a debt-to-equity ratio of 29.19. The stock has a 50-day moving average of $2.30 and a 200 day moving average of $1.71.
Large investors have recently bought and sold shares of the business. Cutter & CO Brokerage Inc. purchased a new stake in Valeritas in the second quarter valued at $116,000. Geode Capital Management LLC raised its position in Valeritas by 138.0% in the fourth quarter. Geode Capital Management LLC now owns 186,971 shares of the company’s stock valued at $60,000 after purchasing an additional 108,416 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in Valeritas in the second quarter valued at $68,000. Institutional investors own 23.91% of the company’s stock.
Valeritas Company Profile (NASDAQ:VLRX)
Valeritas Holdings, Inc, a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization.
See Also: Net Margin
Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.